- Home
- ELVN
as of 03-16-2026 3:59pm EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $41.00 | AVG Volume (30 days): | 647.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | 3.17 |
| 52 Week Low/High: | $13.30 - $30.98 | Next Earning Date: | 06-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 40.06% |
| P/E Ratio: | -15.18 | Index: | N/A |
| Free Cash Flow: | -70459000.0 | FCF Growth: | N/A |
AI-Powered ELVN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
CHIEF MEDICAL OFFICER
Avg Cost/Share
$30.19
Shares
10,129
Total Value
$305,826.92
Owned After
25,000
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$30.02
Shares
29,871
Total Value
$896,811.06
Owned After
25,000
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$29.58
Shares
10,000
Total Value
$295,839.00
Owned After
51,000
SEC Form 4
Director
Avg Cost/Share
$26.18
Shares
1,230
Total Value
$32,196.36
Owned After
22,647
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$26.17
Shares
45,000
Total Value
$1,177,861.50
Owned After
25,000
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$29.04
Shares
5,000
Total Value
$145,219.00
Owned After
740,188
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$26.64
Shares
20,000
Total Value
$535,098.99
Owned After
740,188
Director
Avg Cost/Share
$26.71
Shares
1,230
Total Value
$32,901.52
Owned After
22,647
CHIEF OPERATING OFFICER
Avg Cost/Share
$28.24
Shares
48,300
Total Value
$1,351,762.20
Owned After
215,011
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$27.02
Shares
91,198
Total Value
$2,482,578.16
Owned After
740,188
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Mar 10, 2026 | Sell | $30.19 | 10,129 | $305,826.92 | 25,000 | |
| Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Mar 9, 2026 | Sell | $30.02 | 29,871 | $896,811.06 | 25,000 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Mar 6, 2026 | Sell | $29.58 | 10,000 | $295,839.00 | 51,000 | |
| Heyman Richard A. | ELVN | Director | Feb 17, 2026 | Sell | $26.18 | 1,230 | $32,196.36 | 22,647 | |
| Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sell | $26.17 | 45,000 | $1,177,861.50 | 25,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Feb 6, 2026 | Sell | $29.04 | 5,000 | $145,219.00 | 740,188 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 20, 2026 | Sell | $26.64 | 20,000 | $535,098.99 | 740,188 | |
| Heyman Richard A. | ELVN | Director | Jan 20, 2026 | Sell | $26.71 | 1,230 | $32,901.52 | 22,647 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jan 9, 2026 | Sell | $28.24 | 48,300 | $1,351,762.20 | 215,011 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 9, 2026 | Sell | $27.02 | 91,198 | $2,482,578.16 | 740,188 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 3, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 3, 2026 · 100% conf.
1D
-2.53%
$28.02
Act: +4.28%
5D
-6.80%
$26.80
20D
-3.05%
$27.87
8-K
false000167261900016726192026-03-032026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 03, 2026
Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39247
81-1523849
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6200 Lookout Road
Boulder, Colorado
80301
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 720 647-8519
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ELVN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 3, 2026, Enliven Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number
Exhibit Description
99.1
Press Release issued on March 3, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Enliven Therapeutics, Inc.
Date:
March 3, 2026
By:
/s/ Richard Fair
Name:
Richard Fair
Title:
President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K/A Nov 13, 2025
Q3 2025 Earnings
8-K/ANov 13, 2025
8-K/A
true000167261900016726192025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2025
Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39247
81-1523849
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6200 Lookout Road
Boulder, Colorado
80301
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 720 647-8519
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ELVN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note Enliven Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to the Current Report on Form 8-K originally filed by the Company with the Securities and Exchange Commission on November 12, 2025 to correct the press release attached as Exhibit 99.1 and incorporated herein by reference. Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, the Company issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number
Exhibit Description
99.1
Press Release issued on November 12, 2025 (Corrected)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Enliven Therapeutics, Inc.
Date:
November 12, 2025
By:
/s/ Samuel Kintz
Name:
Samuel Kintz
Title:
President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 12, 2025
Q3 2025 Earnings
8-KNov 12, 2025
8-K
false000167261900016726192025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2025
Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39247
81-1523849
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6200 Lookout Road
Boulder, Colorado
80301
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: 720 647-8519
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ELVN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, Enliven Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number
Exhibit Description
99.1
Press Release issued on November 12, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Enliven Therapeutics, Inc.
Date:
November 12, 2025
By:
/s/ Samuel Kintz
Name:
Samuel Kintz
Title:
President and Chief Executive Officer
Compare ELVN vs Leading Stocks
See how ELVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.